New european registry aims to unlock mysteries of rare breast disease
NCT ID NCT07422870
First seen Feb 20, 2026 · Last updated Jun 16, 2026 · Updated 13 times
Summary
This study is creating a European registry for people with idiopathic granulomatous mastitis (IGM), a rare inflammatory breast condition that causes pain, redness, and abscesses. Researchers will collect information from 1,000 participants to better understand symptoms, treatments, and long-term outcomes. The goal is to improve diagnosis and care for this poorly understood disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRANULOMATOUS MASTITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Gynecology and Obstetrics University Hospital Schleswig-Holstein
Lübeck, Schleswig-Holstein, 23562, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Hospital Düsseldorf
Düsseldorf, North Rhine-Westphalia, 40225, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.